Cargando…

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma

BACKGROUND: Researches on programmed cell death (PD-1) as neoadjuvant immunotherapy for resectable non-small cell lung cancer is underway, which brings hope for individuals with the disease. However, a study dedicated to lung squamous cell carcinoma (LUSC) specifically has yet to be conducted. Now,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Dijian, Wang, Jiangfeng, Wu, Jie, Chen, Sheng, Li, Jianqiang, Liu, Jinshi, Chen, Qixun, Jiang, Youhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024839/ https://www.ncbi.nlm.nih.gov/pubmed/33841966 http://dx.doi.org/10.21037/jtd-21-103

Ejemplares similares

Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer
por: Zhang, Lin, et al.
Publicado: (2020)

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
por: Wang, Jiangfeng, et al.
Publicado: (2021)

Surgical selection and regional lymph node dissection for stage I second primary lung cancer patients following surgery for stage I first primary lung cancer
por: Wu, Xiao, et al.
Publicado: (2023)

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report
por: Zhang, Shuliang, et al.
Publicado: (2022)

Surgery for stage IIB–IIIB small cell lung cancer
por: Huang, Zhida, et al.
Publicado: (2023)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

A Fifteen‐Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer
por: Tian, Xun, et al.
Publicado: (2021)

Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer
por: Cao, Feiyi, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
por: Zhang, Shujing, et al.
Publicado: (2023)

Long non-coding RNA MCM3AP antisense RNA 1 promotes non-small cell lung cancer progression through targeting microRNA-195-5p
por: Shen, Dijian, et al.
Publicado: (2021)

Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study
por: Feng, Yiding, et al.
Publicado: (2020)

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
por: Xu, Yaping, et al.
Publicado: (2012)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
por: Wang, Kai, et al.
Publicado: (2023)

Management of type IIB and IIIB olecranon fractures. Case series
por: Ali, Mohammed, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients
por: Puspitasari, Irma M, et al.
Publicado: (2021)

Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma
por: Fan, Yun, et al.
Publicado: (2016)

Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy
por: Xu, Liwei, et al.
Publicado: (2022)

Clinical outcomes observation in stage IIB–IIIB cervical cancer treated by adjuvant surgery following concurrent chemoradiotherapy
por: Li, Yong, et al.
Publicado: (2021)

Comparison of Neoadjuvant Intraarterial Chemotherapy Versus Concurrent Chemoradiotherapy in Patients With Stage IIIB Uterine Cervical Cancer
por: Kawaguchi, Ryuji, et al.
Publicado: (2013)

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores
por: Feng, Jifeng, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for elderly patients with non-small-cell lung cancer: a case report and literature review
por: Li, Jianqiang, et al.
Publicado: (2021)

Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
por: Zhao, Guangyin, et al.
Publicado: (2023)

Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer
por: Marchetti, Claudia, et al.
Publicado: (2018)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

Neoadjuvant Radiation with Concurrent 5-FU Resulting in Complete Pathologic Response in Stage IIIB Squamous Cell Carcinoma of the Urethra
por: Suthar, Krishna H., et al.
Publicado: (2020)

The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma
por: Wang, Ying, et al.
Publicado: (2022)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
por: Duan, Hongtao, et al.
Publicado: (2022)

Role of chemotherapy in stage IIb nasopharyngeal carcinoma
por: Pan, Xin-Bin, et al.
Publicado: (2012)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

The Effect of Neoadjuvant Chemotherapy on Lymph Node Metastasis of FIGO Stage IB1-IIB Cervical Cancer: A Systematic Review and Meta-Analysis
por: Chen, Bingxin, et al.
Publicado: (2020)

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
por: Zhou, Nan, et al.
Publicado: (2023)

Prognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy
por: Huang, Kecheng, et al.
Publicado: (2016)

Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients
por: Zhao, Feng-Ju, et al.
Publicado: (2021)

Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer
por: Yamaguchi, Kensei, et al.
Publicado: (2022)

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
por: Yang, Zhang-Ru, et al.
Publicado: (2020)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
por: Liu, Pingping, et al.
Publicado: (2022)

What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?
por: Chen, Qichen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u6vdflg2r0j6vbad1ovethdaen